盆腔MRI在子宫内膜癌FIGO 2023分期中的回顾性评估
这项双中心回顾性研究纳入231例经活检证实的子宫内膜癌患者,均行腹盆腔MRI检查,比较术前影像分期与术后病理分期在FIGO 2009与FIGO 2023两版系统下的一致性。结果显示FIGO 2023使主要分期一致率从86.6%降至76.2%,亚分期一致率从74.0%降至56.3%,分子分型使15.2%患者被重新分期。
要点
- FIGO 2023引入分子分型后,术前MRI与病理的亚分期一致率显著下降至56.3%
- 轻微肌层浸润和微转移淋巴结是MRI漏判导致不一致的最常见原因
- 约9.5%患者的初始治疗方案可能因分期不一致而改变
核心结论
- FIGO 2023更新降低了术前盆腔MRI与最终病理的亚分期一致率
- 不一致主要由轻微肌层浸润和微转移淋巴结的漏检所致
研究设计与样本
- 双中心回顾性研究,纳入231例活检证实的子宫内膜癌女性,中位年龄63岁(IQR 55-73岁)
- 所有患者行腹盆腔MRI检查,依据MRI及活检分级和组织学类型确定影像FIGO 2009分期
- 手术标本结合分子状态确定病理FIGO 2009与FIGO 2023分期
关键影像表现/征象
- 轻微肌层浸润在FIGO 2023不一致病例中占36.6%(37/101),是最常见的影像漏判征象
- 淋巴结受累在不一致病例中占17.8%(18/101),MRI难以检出微转移
诊断标准与关键数值
- 分子数据使35/231(15.2%)患者被重新分期,其中18例降期,17例升期
- 不一致病因:轻微肌层浸润占36.6%(37/101),组织学改变占18.8%(19/101),淋巴结受累占17.8%(18/101),淋巴血管间隙浸润占11.9%(12/101)
临床应用与阅片要点
- 报告时应明确MRI对轻微肌层浸润和微转移淋巴结检出的固有局限
- 分期不一致可能改变22/231(9.5%)患者的初始治疗方案,阅片时需提示临床结合分子分型
- 影像分期与病理分期在FIGO 2023下亚分期一致率仅56.3%,报告结论应留有余地
局限性
- 回顾性研究设计本身存在选择偏倚可能
- 分子分型信息在影像检查时不可见,影像分期无法整合该变量
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer (EC) integrates histopathologic and molecular variables that may be inapparent at imaging. Purpose To evaluate the impact of the updated FIGO 2023 staging system on preoperative MRI assessment in patients with EC, and to assess its impact on patient outcomes. Materials and Methods In this dual-center retrospective study, women with biopsy-proven EC underwent abdominal MRI. Radiologic FIGO (rFIGO) 2009 stage was assigned from MRI and biopsy grade and histotype. Surgical specimens provided pathologic FIGO (pFIGO) 2009 and 2023 stages, incorporating molecular status. Concordance and causes of discordance were assessed. Potential impact on initial management was inferred using 2025 European Society of Gynaecological Oncology-European Society for Radiotherapy and Oncology-European Society of Pathology guidelines. Disease-free survival (DFS) and overall survival (OS) were assessed with Kaplan-Meier. Results A total of 231 women (median age, 63 years; IQR, 55-73 years) were evaluated. Major-stage agreement decreased from 86.6% (200 of 231) of patients for rFIGO 2009 versus pFIGO 2009 to 76.2% (176 of 231) for rFIGO 2023 versus pFIGO 2023 (P < .001); substage concordance declined from 74.0% (171 of 231) with FIGO 2009 to 56.3% (130 of 231) with FIGO 2023 (P < .001). Under FIGO 2023, the most common causes of discordance were minimal myometrial invasion (37 of 101 women, 36.6%), lymph node involvement (18 of 101 women, 17.8%), and histology-dependent factors such as lymphovascular space invasion (12 of 101 women, 11.9%) and histologic changes (19 of 101 women, 18.8%). Molecular data reclassified 35 of the 231 (15.2%) patients (18 patients were downstaged; 17 were upstaged). Discrepancies would have altered the initial approach in 22 of the 231 (9.5%) patients. Recurrence and death occurred in 18 (7.8%) and 16 (7.0%) of the 231 patients, respectively, with DFS and/or OS stratification across radiologic and pathologic 2009 and 2023 stages (all P < .001). Conclusion The 2023 FIGO update reduced substage concordance between preoperative pelvic MRI and final pathology, primarily due to the missed detection of minimal myometrial invasion and micrometastatic lymph node involvement. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Kataoka and Himoto in this issue.
引用
- Avesani, Bonatti, Bottazzi, et al. Pelvic MRI in Endometrial Cancer Staging: A Retrospective Evaluation of the Impact of FIGO 2023. Radiology. 2026. PMID: 42377124. doi:10.1148/radiol.252037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。